ExonanoRNA, LLC was established in 2017 to fill a market gap for the commercial production of high-quality RNA nanoparticles for research and pre-clinical development. RNA nanotechnology allows the integration of multiple functional RNA modules into one nanoparticle, of which the scaffold, ligand, therapeutic moieties, and regulator can be composed predominantly or exclusively of RNA. Our core activities include research and develop of a broad range of innovative products in the primary area of RNA nanotechnology-based platforms for next generation targeted drug delivery and disease diagnosis. Our team is comprised of experienced scientists that efficiently coordinate a multidisciplinary effort to transition bio-nanotechnology, especially RNA nanotechnology from the bench to the clinic.